In an interview on the latest scientific development aimed at assessing the safety and effectiveness of medicine in African populations, a local Scientist, Professor Collen Masimirembwa who is the president and chief Scientific officer with the African Institute of Biomedical Science and Technology (AIBST) has said that over 20 percent of Africans taking Efavirenz, a first line antiretrovals drugs used in the management of HIV and AIDS could be taking and overdose, adding that over 20 percent of the patients in Zimbabwe and in Africa for that matter, are overdose when they are being given the current standard dose. Prof. Masimirembwa has said that AIBST had come up with a genetic test to ascertain the possibility of reduction of Efavirenz dose in the product to match with the African genetic make-up to reduce side effects.

No Comments

Leave a Comment